@upside_invest: Eli Lilly's obesity pill just passed a sleep apnea trial it wasn't originally built for. Breathing interruptions down up to 44%, plus 28 pounds lost on average. FDA filing expected before year-end, putting a second blockbuster label on the clock. On Upside, 72% of recent LLY trades have been buys. If you want to see what other investors are doing in real time, comment “upside” and ill send you the link. And follow upside invest for more news breakdowns every single day. #investing #portfolio #stocks #upside #stockmarket
Foundayo is still an incremental addition rather than a primary driver of Lilly’s valuation. The company’s core growth and market dominance come from the injectable franchise (Mounjaro + Zepbound). And Lilly (LLY) is ~1,440 a share. NVO/RMD maybe.
2026-11-16 19:16:00
1
K_nite80s_baby :
my friend is starting Zepbound. she failed sleep apena test and is obese so she qualifies. im curious see how this is going effect the market.
2026-11-16 20:44:02
2
Ezio :
is it the cause of reduce sleep apnea or is it an effect of weight loss?
2026-11-17 06:01:41
0
user3703302497512 :
At what dose did it have an impact on the apnea?
2026-11-16 23:47:38
0
Dr.Saczawa :
foundayo made all of my extended-release meds stop working (zepbound did not)
2026-11-16 23:31:47
0
glorious.porpoise :
Cant come fast enough.
2026-11-16 20:56:04
0
Amy🏳️🌈 :
I just took glp-1 shots and lost 75lbs and don't have sleep apnea anymore. Ypu don't have to have their lil pill
2026-11-16 21:47:40
0
gfs110 :
and it will be banned because they make way too much from the machines
2026-11-17 02:21:15
0
To see more videos from user @upside_invest, please go to the Tikwm
homepage.